• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed, refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018, 19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1.

home / authors / moreau-p-mateos-mv-berenson-jr-et-al-once-weekly-versus-twice-weekly-carfilzomib-dosing-in-patients-with-relapsed

Articles

© 2024 MJH Life Sciences
AJMC®
All rights reserved.